Inception Therapeutics is a biotechnology company dedicated to developing disease-modifying therapies for neurodegenerative diseases. The company's primary focus is on NLRP3 inflammasome inhibitors designed specifically for central nervous system applications, with an initial emphasis on Parkinson's disease.
| Attribute | Value |
|---|---|
| Founded | 2020 |
| Headquarters | San Diego, California, USA |
| CEO | Dr. Robert H. Brown |
| Funding | Series A ($32M, 2021) |
| Focus | CNS NLRP3 inhibitors |
| Stage | Preclinical |
Inception Therapeutics was founded by leading neuroscientists from UC San Diego and The Scripps Research Institute:
The company's name reflects its "inception" concept—starting from the fundamental biology of neuroinflammation to create transformative therapies.
Inception's platform is specifically designed for brain applications:
Inception's approach targets the specific neuroinflammatory pathways active in PD:
| Program | Mechanism | Indication | Stage | Status |
|---|---|---|---|---|
| INN-101 | NLRP3 inhibitor | Parkinson's disease | Preclinical | IND-enabling |
| INN-102 | NLRP3 inhibitor | Alzheimer's disease | Discovery | Lead optimization |
| INN-103 | NLRP3/TREM2 dual | ALS | Discovery | Early stage |
INN-101 is Inception's lead program:
Preclinical efficacy in MPTP model:
INN-102 is optimized for Alzheimer's disease pathology:
Inception has established key academic partnerships:
| Round | Amount | Year | Investors |
|---|---|---|---|
| Series A | $32M | 2021 | ARCH Venture, Omega Funds, MPM Capital |
Inception positions itself as the "CNS-first" NLRP3 company:
| Company | Focus | Inception Differentiation |
|---|---|---|
| Inception | CNS-only, brain-penetrant | Dedicated CNS optimization |
| Olacteant | Peripheral + CNS | Broader, less CNS-specific |
| NodThera | CNS (NT-0796) | Earlier stage |
| Ventus | NLRP3 + Gasdermin | Different mechanism |